TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
Elixir shares 8 Presentations highlighting company's transformational technology innovations at TCT 2023.
Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023
The DESyne BDS Plus RCT includes 202 patients across 14 sites in Europe, New Zealand and Brazil.
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments That Uncage the Stented Artery
Elixir Reveals New Category of ‘Bioadaptive Drug Eluting Stents’ (BA- DES), Sharing DynamX Technology, Preclinical Data, and Clinical Program at 29th Transcatheter Cardiovascul
Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced toda
Successful Live Case Demonstration of Elixir Medical’s Fully Bioresorbable DESolve NXT Plus Novolimus Eluting Coronary Scaffold System at TCT
Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced toda
Elixir Medical Announces Successful Live Case Transmission of DESolve Cx at TCT
Sunnyvale, Calif. – October 13, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, annou